Evonik Idles US SAP Plants

(c) Evonik
(c) Evonik

Poor market conditions have forced Germany’s Evonik to scale back production of superabsorbent polymers (SAP) in the US. Production lines at the company’s plants in Garyville and Greensboro, North Carolina, are to be idled in response to lower demand, removing 40,000 t/y of capacity and taking total output down to 530,000 t/y. Timing for the lines’ closure was not disclosed.

“With this measure we’re adapting to demand trends. We plan to take the opportunity to bring capacity to the technological state of the art and to start up the lines again in 1-2 years,” said Norbert Westerholt, head of Evonik’s Baby Care business line. Global demand growth for SAP is expected to grow by about 6-7% per year through 2020, according to analysis by information provider IHS, but demand in the mature markets of North America and northwest Europe will stay fairly flat.

Evonik has five superabsorbents sites worldwide. As well as the two US plants, it has SAP production at Krefeld and Rheinmünster in Germany, and in a joint venture – Saudi Acrylic Polymers – in Jubail, Saudi Arabia.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.